Kenneth T. Mills - Sep 27, 2021 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
President and CEO, Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Sep 27, 2021
Transactions value $
-$57,645
Form type
4
Date filed
9/29/2021, 04:19 PM
Previous filing
Sep 15, 2021
Next filing
Nov 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $5.64K +1.5K +0.53% $3.76* 282K Sep 27, 2021 Direct F1
transaction RGNX Common Stock Sale -$63.3K -1.5K -0.53% $42.19 281K Sep 27, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -1.5K -0.64% $0.00 231K Sep 27, 2021 Common Stock 1.5K $3.76 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.